Merosin-deficient congenital muscular dystrophy type 1A: A case report

He,Zhanwen; Luo,Xiangyang; Liang,Liyang; Li,Pinggan; Li,Dongfang; Zhe,Meng

doi:10.3892/etm.2013.1271

Merosin-deficient congenital muscular dystrophy type 1A: A case report

Authors:
- Zhanwen He
- Xiangyang Luo
- Liyang Liang
- Pinggan Li
- Dongfang Li
- Meng Zhe
View Affiliations

Affiliations: Department of Pediatrics, Sun Yat-sen Memorial Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China
Published online on: August 23, 2013 https://doi.org/10.3892/etm.2013.1271
Pages: 1233-1236

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to characterize the clinical and genetic features of a 4-year‑old female with merosin‑deficient congenital muscular dystrophy type 1A (MDC1A). MDC1A is the most common form of congenital muscular dystrophy. MDC1A is caused by mutation of the laminin α-2 gene (LAMA2), localized to chromosome 6q22-23. Clinical presentation, as well as the results of neuroimaging, electrophysiology and molecular genetic tests were used to evaluate a patient with MDC1A. The patient exhibited severe hypotonia and marked proximal weakness at 6 months of age, as well as delayed developmental milestones. The serum creatine kinase levels of the patient were elevated at 1,556 IU/l. Magnetic resonance imaging (MRI) showed that the white matter in the frontal, parietal, temporal and occipital lobes was abnormal with low signal intensities on T1-weighted images and high signal intensities on T2-weighted images; however, the cortex was normal. Sequencing of the 65 exons of the LAMA2 revealed a homozygous nonsense mutation in exon 50: a C>T exchange in nucleotide 7147 that resulted in a stop codon (Arg2383X stop). Molecular genetic testing is a reliable method for confirming a diagnosis of MDC1A. When a patient presents with severe congenital hypotonia, muscle weakness, high serum creatine kinase (CK) levels and white matter abnormalities, the evaluation may directly proceed to molecular genetic testing of the LAMA2 gene without performing a muscle biopsy.

View Figures

View References

1.	Banker BQ and Engel AG: Basic reactions of muscle. Myology: Basic and Clinical. Engel AG and Franzini-Armstrong C: 3rd edition. McGraw-Hill; New York, NY: pp. 691–748. 2004
2.	Tomé FM, Evangelista T, Leclerc A, et al: Congenital muscular dystrophy with merosin deficiency. C R Acad Sci III. 317:351–377. 1994.
3.	Xiong H, Yao S, Yuan Y, et al: Diagnosis of congenital muscular dystrophy and clinical significance of merosin expression. Zhonghua Er Ke Za Zhi. 44:918–923. 2006.(In Chinese).
4.	Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, Bittner C and Fialka-Moser V: Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med. 40:665–671. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Voit T and Tomé FS: The congenital muscular dystrophies. Myology: Basic and Clinical. Engel AG and Franzini-Armstrong C: 3rd edition. McGraw-Hill; New York, NY: pp. 1203–1238. 2004
6.	Mostacciuolo ML, Miorin M, Martinello F, et al: Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy. Hum Genet. 97:277–279. 1996. View Article : Google Scholar : PubMed/NCBI
7.	Jones KJ, Morgan G, Johnston H, et al: The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet. 38:649–657. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Sparks S, Quijano-Roy S, Harper A, et al: Congenital Muscular Dystrophy Overview. GeneReviews™ [Internet]. Pagon RA, Adam MP, Bird TD, et al: University of Seattle; Seattle, WA: 2001, http://www.ncbi.nlm.nih.gov/books/NBK1291/uri.
9.	Di Muzio A, De Angelis MV, Di Fulvio P, et al: Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy. Muscle Nerve. 27:500–506. 2003.PubMed/NCBI
10.	Philpot J, Sewry C, Pennock J and Dubowitz V: Clinical phenotype in congenital muscular dystrophy: correlation with expression of merosin in skeletal muscle. Neuromusc Disord. 5:301–305. 1995. View Article : Google Scholar : PubMed/NCBI
11.	Sijens PE, Fock JM, Meiners LC, et al: MR spectroscopy and diffusion tensor imaging of the brain in congenital muscular dystrophy with merosin deficiency: metabolite level decreases, fractional anisotropy decreases, and apparent diffusion coefficient increases in the white matter. Brain Dev. 29:317–321. 2007. View Article : Google Scholar
12.	Brockmann K, Dechent P, Bönnemann C, et al: Quantitative proton MRS of cerebral metabolites in laminin alpha2 chain deficiency. Brain Dev. 29:357–364. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Sunada Y, Edgar TS, Lotz BP, et al: Merosin-negative congenital muscular dystrophy associated with extensive brain abnormalities. Neurology. 45:2084–2089. 1995. View Article : Google Scholar : PubMed/NCBI
14.	Fardeau M, Tomé FM, Helbling-Leclerc A, et al: Congenital muscular dystrophy with merosin deficiency: clinical, histopathological, immunocytochemical and genetic analysis. Rev Neurol (Paris). 52:11–19. 1996.(In French).
15.	Helbling-Leclerc A, Zhang X, Topaloglu H, et al: Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet. 11:216–218. 1995. View Article : Google Scholar : PubMed/NCBI
16.	Burgeson RE, Chiquet M, Deutzmann R, et al: A new nomenclature for the laminins. Matrix Biol. 14:209–211. 1994. View Article : Google Scholar : PubMed/NCBI
17.	Di Blasi C, Piga D, Brioschi P, et al: LAMA2 gene analysis in congenital muscular dystrophy: new mutations, prenatal diagnosis, and founder effect. Arch Neurol. 62:1582–1586. 2005.PubMed/NCBI